Joshua J Crose, Arezou Crose, John T Ransom, Amy L Lightner
{"title":"骨髓间充质干细胞衍生的细胞外囊泡输注治疗肌萎缩性脊髓侧索硬化症。","authors":"Joshua J Crose, Arezou Crose, John T Ransom, Amy L Lightner","doi":"10.1080/17582024.2024.2344396","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> In this pilot safety study, we hypothesized that a human bone marrow stem cell-derived extracellular vesicle (hBM-MSC EV) investigational product (IP) would be safe and exhibit potential efficacy in amyotrophic lateral sclerosis (ALS) patients.<b>Methods:</b> Ten ALS patients received two 10-ml intravenous infusions of the IP given 1 month apart and evaluated over 3 months.<b>Results:</b> There were no serious adverse events or adverse events related to the IP and 30% of subjects' ALS functional rating scale-revised (ALSFRS-R) scores did not decline.<b>Conclusion:</b> HBM-MSC EVs appear safe in ALS patients. This early investigation suggests a controlled study of EVs for the treatment of ALS is warranted.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"14 3-4","pages":"111-117"},"PeriodicalIF":2.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457643/pdf/","citationCount":"0","resultStr":"{\"title\":\"Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for amyotrophic lateral sclerosis.\",\"authors\":\"Joshua J Crose, Arezou Crose, John T Ransom, Amy L Lightner\",\"doi\":\"10.1080/17582024.2024.2344396\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> In this pilot safety study, we hypothesized that a human bone marrow stem cell-derived extracellular vesicle (hBM-MSC EV) investigational product (IP) would be safe and exhibit potential efficacy in amyotrophic lateral sclerosis (ALS) patients.<b>Methods:</b> Ten ALS patients received two 10-ml intravenous infusions of the IP given 1 month apart and evaluated over 3 months.<b>Results:</b> There were no serious adverse events or adverse events related to the IP and 30% of subjects' ALS functional rating scale-revised (ALSFRS-R) scores did not decline.<b>Conclusion:</b> HBM-MSC EVs appear safe in ALS patients. This early investigation suggests a controlled study of EVs for the treatment of ALS is warranted.</p>\",\"PeriodicalId\":19114,\"journal\":{\"name\":\"Neurodegenerative disease management\",\"volume\":\"14 3-4\",\"pages\":\"111-117\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457643/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurodegenerative disease management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17582024.2024.2344396\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17582024.2024.2344396","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：在这项安全性试验研究中，我们假设人骨髓干细胞衍生的细胞外囊泡(hBM-MSC EV)研究产品(IP)对肌萎缩性脊髓侧索硬化症(ALS)患者是安全的，并具有潜在疗效：10名ALS患者接受了两次10毫升的IP静脉注射，每次间隔1个月，并在3个月内进行评估：结果：没有发生与 IP 有关的严重不良事件或不良反应，30% 的受试者的 ALS 功能评分表（ALSFRS-R）评分没有下降：结论：HBM-间充质干细胞 EVs 对 ALS 患者似乎是安全的。结论：HBM-间充质干细胞对 ALS 患者似乎是安全的。这项早期调查表明，有必要对 EVs 治疗 ALS 进行对照研究。
Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for amyotrophic lateral sclerosis.
Background: In this pilot safety study, we hypothesized that a human bone marrow stem cell-derived extracellular vesicle (hBM-MSC EV) investigational product (IP) would be safe and exhibit potential efficacy in amyotrophic lateral sclerosis (ALS) patients.Methods: Ten ALS patients received two 10-ml intravenous infusions of the IP given 1 month apart and evaluated over 3 months.Results: There were no serious adverse events or adverse events related to the IP and 30% of subjects' ALS functional rating scale-revised (ALSFRS-R) scores did not decline.Conclusion: HBM-MSC EVs appear safe in ALS patients. This early investigation suggests a controlled study of EVs for the treatment of ALS is warranted.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
